One woman shares about the narcolepsy symptoms that disrupted her life, and the journey to a diagnosis: "I'm living proof you ...

LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

Have you ever experienced something like this? In the comments below or via this anonymous form, tell us about the "unusual" ...

Anecdotal evidence has long suggested that sleep problems are especially common for people with Moebius syndrome. Now, a new ...

HC Wainwright issued their Q1 2025 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Monday, March 10th. HC Wainwright analyst O. Livnat forecasts that ...

Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price target upped by HC Wainwright from $200.00 to $217.00 in a ...

Limited or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' ...

Drivers are being warned that failure to inform the DVLA about a health diagnosis, and any subsequent changes in health, can ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the ...

In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control. When patients experience intense emotion, either positive or ...

Wakix was first approved in 2019 for EDS with narcolepsy, then picked up another nod in 2020 for cataplexy in narcolepsy patients. The company expanded its drug's use to pediatric patients for EDS ...